U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07547228) titled 'Phase I/II Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)' on April 17.
Brief Summary: Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).
PRL3-zumab will be administered Intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms.
Arm-1: PRL3-zumab 3mg/kg intravenously in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously in 2...